Studies

This area is currently being rebuilt by us. You will receive more information on the ongoing studies here shortly.

 
 

 Clinical Studies - First-line studies

TRIANGLE

Randomized, three-arm, parallel-group, open label, international phase III trial comparing six alternating courses of R-CHOP/R-DHAP (one cycle every 21 days) followed by ASCT versus the combination with ibrutinib in induction and maintenance (2 years) or the experimental arm without ASCT

Prospective Randomized Comparison of Myeloablative Radiochemotherapy followed
by Blood Stem Cell Transplantation versus Maintenance with Interferon alpha

Download recruitment (2020-07-01)

Download protocol (2019-11-19)

 

MCL R2 Elderly - Recruitment stopped!

Efficacy of alternating immunochemotherapy consisting of R-CHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of additional lenalidomide with rituximab versus rituximab alone for older patients with mantle cell lymphoma

Download recruitment (2020-02-12)

Download protocol (2019-06-24)

 

MCL Younger - Recruitment stopped!

Efficacy of 6 courses CHOP plus Rituximab followed by myeloablative radiochemotherapy and autologous stem cell transplantation versus alternating courses of 3x CHOP and 3x DHAP plus Rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation

Download recruitment (2011-10-22)

 

MCL Elderly / MCL autologous SCT - Recruitment stopped!

Efficacy of maintenance therapy with rituximab after induction chemotherapy (R-CHOP vs. R-FC) for elderly patients with mantle cell lymphoma not suitable for stem cell transplantation

Download recruitment (2004-10-09)

Download protocol (2000-11-02)

 Clinical Studies - Relapse studies

SAKK 36/13
Combination of ibrutinib and bortezomib followed by ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma; a multicenter Phase I/II trial

Download protocol (2019-03-11)

 

R-HAD-Studie (MCL 2005-01) - Recruitment stopped!

Efficacy and safety of RITUXIMAB, High-Dose ARA-C and DEXAMETHASONE (R-HAD) alone or in combination with BORTEZOMIB in patients with relapsed oder refractory Mantle Cell Lymphoma

Download recruitment (2019-03-28)

 

Zevalin-Study - Recruitment stopped!

Efficacy and safety of 90Y-ibritumomab tiuxetan in patients with refractory or relapsed mantle cell lymphoma after / not appropriate for autologous stem cell transplantation
Attention: This study is closed!

Corporate Partners - Individual Sponsors
Sat, 05th December 2020 to Tue, 08th December 2020
62nd ASH Annual Meeting and Exposition
more dates
Tue, 23rd June 2020
The 1st Czernecki Donnelly Prize was awarded to Elisabeth Silkenstedt
more news